Generic Name and Formulations:
Mecasermin 10mg/mL; soln for SC inj; contains benzyl alcohol.
Ipsen Biopharmaceuticals, Inc.
Indications for INCRELEX:
Growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or in those with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Closed epiphyses: not recommended.
Administer before or after (+/–20 minutes) a meal/snack; rotate inj sites. <2yrs: not established. ≥2yrs: initially 0.04 to 0.08mg/kg SC twice daily; may increase after 1-week by 0.04mg/kg per dose; max 0.12mg/kg per dose twice daily.
Recombinant human insulin-like growth factor-1 (rhIGF-1).
Growth promotion in patients with closed epiphyses. Active or suspected neoplasia. IV administration.
Not for secondary forms of IGF-1 deficiency. Correct thyroid and nutritional deficiences before treatment. Measure preprandial glucose level before treatment and monitor until a tolerated dose is established. Reduce dose if hypoglycemia occurs despite adequate food intake with therapy. Monitor for lymphoid tissue hypertrophy complications. Do funduscopic exam for intracranial hypertension at the start of therapy, then periodically. Evaluate any child with onset of limp or hip/knee pain for possible slipped capital femoral epiphysis. Monitor for progression of scoliosis. Pregnancy (Cat.C). Nursing mothers.
Hypoglycemia, local/systemic hypersensitivity (including anaphylaxis), lymphoid tissue hypertrophy (eg, tonsillar and adenoidal hypertrophy); intracranial hypertension.
Multidose vial (40mg/vial)—1